Landmark Japanese Trial Shows Lab-Grown Stem Cells Restored Movement in Paralyzed Patients — and Stayed Safe for Up to Four Years

What This Article Covers

On July 21, 2026, researchers at Keio University in Japan, led by longtime spinal cord regeneration pioneer Dr. Hideyuki Okano, published long-awaited long-term results in Nature Medicine from the world's first clinical trial to transplant induced pluripotent stem cell (iPSC)-derived neural stem/progenitor cells directly into the injured spinal cords of patients with acute, complete paralysis. Four years after the first patients received their transplants, the team reports that the cells appear to remain safe — with no tumors and no serious graft-related complications — while half of the small four-patient cohort experienced neurological improvement that outpaced what would typically be expected without treatment. This is an early, safety-focused study, not proof that the therapy restores function, but it is a genuinely important milestone: it is the longest-followed human safety dataset anywhere for an iPSC-derived cell transplant in the spinal cord, and it clears a major hurdle on the path toward larger, controlled efficacy trials.

What Happened

Keio University's Regenerative Medicine Research Center has spent more than a decade building toward this moment. The team manufactured neural stem/progenitor cells (iPSC-NS/PCs) under Good Manufacturing Practice (GMP) conditions from an integration-free induced pluripotent stem cell line established from umbilical cord blood, using a donor selected specifically because they carry an HLA haplotype common in the Japanese population — a strategy meant to reduce (though not eliminate) the risk of immune rejection in future patients. Between roughly 2022 and 2023, surgeons injected two million of these cells directly into the injury site of four men, ages 26 to 66, each of whom had suffered a traumatic, complete cervical spinal cord injury (AIS grade A — the most severe classification, involving total loss of motor and sensory function below the injury) two to four weeks earlier. All four completed the initial 52-week study period and have now been followed for two to four years.

The Data Behind the Headlines

The primary goal of this Phase 1 trial was safety, not effectiveness, and on that front the results are clean: no tumor formation and no serious adverse events were attributed to the transplanted cells, either during the first year or across the extended two-to-four-year follow-up. Repeated MRI and PET imaging showed no evidence of abnormal cell proliferation. Immunosuppression with tacrolimus was given for a limited window — starting the day before surgery and tapered off by nine months — and even patients with poor HLA matches to the donor cell line showed little sign of immune rejection.

On the exploratory efficacy side, the numbers are the kind that warrant real, if measured, optimism. By week 52, patients had gained a median of 13 points on the standard ISNCSCI motor scoring scale, with most improvement occurring in the first three months. Two of the four patients converted from AIS grade A to a less severe grade (one to grade C, one to grade D) — meaning they regained at least some voluntary motor or sensory function below the injury level. For context, the researchers compared this to a historical registry of 52 similar patients who did not receive the therapy, in which only about 15% achieved that same degree of improvement. Sensory function and scores on the SCIM-III functional independence scale also improved across all four participants and remained stable through long-term follow-up.

Regulatory and Clinical Context

This is an investigator-initiated academic study, not an industry-sponsored pivotal trial, and it has not led to any approval or marketing authorization anywhere. Japan's regulatory system does allow for a distinct conditional approval pathway for regenerative medicine products, and Okano's group has previously signaled intentions to move this approach toward that pathway and toward larger trials — including, per companion research presented at the 2026 ISSCR Annual Meeting, an expansion toward patients with chronic (rather than only subacute) spinal cord injury. But that is future work; this paper reports only the completed four-patient subacute study and its long-term follow-up.

What It Means for Patients

For the roughly 300,000 Americans and millions of people worldwide living with spinal cord injury — a condition for which no FDA-approved regenerative treatment currently exists — this result matters less for its size than for what it establishes: that lab-grown neural cells derived from stem cells can be surgically placed into an acutely injured human spinal cord and remain safe for years, without triggering tumors or catastrophic immune reactions. That safety foundation is what every larger, controlled trial needs before it can even begin. For patients and families searching for options today, the honest takeaway is that this is not yet an available treatment — it remains an experimental, hospital-based surgical procedure open (so far) only within a tightly controlled Japanese research protocol, restricted to a specific injury type, level, and window after injury.

Honest Caveats and Limitations

The authors themselves are candid about the limits of what this study can show. With only four patients and no placebo or untreated control arm run in parallel, the trial cannot prove the cell transplant caused the motor recovery — the comparison to a historical patient registry is suggestive, not definitive, and some natural spontaneous recovery is expected after any spinal cord injury, particularly incomplete or borderline cases. The researchers also could not directly confirm, through tissue biopsy, that the transplanted cells actually survived, matured into neurons, and functionally integrated into the patient's own spinal circuitry — the imaging tools available in living patients cannot fully answer that question. All four participants were Japanese men, limiting what can be said about how the therapy might perform in women or other populations. And while four years is an unusually long follow-up for a cell-therapy safety study, delayed tumor formation or immune complications occurring later still cannot be ruled out.

Bottom Line

This is a small, safety-focused Phase 1 study — not an approved therapy, and not proof that iPSC-derived cell transplants restore movement after spinal cord injury. But it is a genuinely encouraging, rigorously documented milestone: the longest human safety follow-up yet reported for an iPSC-derived neural cell transplant, paired with exploratory recovery data that outperformed a historical comparison group in half the treated patients, all without a single tumor or serious cell-related complication in up to four years of watching. That combination — real safety data over real time, alongside a genuine (if preliminary) efficacy signal — is exactly the kind of foundation that has to be built before this approach can responsibly move into the larger, controlled trials that would be needed to know whether it truly works.